Claims
- 1. A method of treating the symptoms of autism comprising the step of administering an effective amount of anti-rubeola antibody.
- 2. The method of claim 1 wherein said anti-rubeola antibody is a monoclonal antibody.
- 3. The method of claim 1 wherein said anti-rubeola antibody is administered orally.
- 4. The method of claim 3 wherein said anti-rubeola antibody is administered by oral drench.
- 5. The method of claim 3 wherein said anti-rubeola antibody is administered sublingually.
- 6. The method of claim 3 wherein said anti-rubeola antibody is administered in an enterically protected form.
- 7. The method of claim 1 wherein said anti-rubeola antibody is administered at a dosage of from 0.1 mg to 10 mg per dose.
- 8. A method of treating the symptoms of multiple sclerosis comprising the step of administering an effective amount of anti-rubeola antibody.
- 9. The method of claim 8 wherein said anti-rubeola antibody is a monoclonal antibody.
- 10. The method of claim 8 wherein said anti-rubeola antibody is administered orally.
- 11. The method of claim 10 wherein said anti-rubeola antibody is administered by oral drench.
- 12. The method of claim 10 wherein said anti-rubeola antibody is administered sublingually.
- 13. The method of claim 10 wherein said anti-rubeola antibody is administered in an enterically protected form.
- 14. The method of claim 8 wherein said anti-rubeola antibody is administered at a dosage of from 0.1 mg to 10 mg per dose.
- 15. A method of treating the symptoms of a disease state selected from the group consisting of attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) comprising the step of administering an effective amount of anti-rubeola antibody.
- 16. The method of claim 15 wherein said anti-rubeola antibody is a monoclonal antibody.
- 17. The method of claim 15 wherein said anti-rubeola antibody is administered orally.
- 18. The method of claim 17 wherein said anti-rubeola antibody is administered by oral drench.
- 19. The method of claim 17 wherein said anti-rubeola antibody is administered sublingually.
- 20. The method of claim 17 wherein said anti-rubeola antibody is administered in an enterically protected form.
- 21. The method of claim 15 wherein said anti-rubeola antibody is administered at a dosage of from 0.1 mg to 10 mg per dose.
- 22. A dosage unit of pharmaceutical composition for administration to a subject for treatment of a disease state selected from the group consisting of autism, multiple sclerosis, attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) comprising anti-rubeola antibody in an amount effective to alleviate one or more symptoms of a disease state selected from the group consisting of autism, multiple sclerosis, attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD);wherein said amount of anti-rubeola antibody is a single dose between 0.1 mg and 10 mg.
Parent Case Info
This application claims priority from U.S. Provisional Application Ser. No. 60/153,838 filed Sep. 14, 1999.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4384993 |
Sato et al. |
May 1983 |
|
4692331 |
Uemaura et al. |
Sep 1987 |
|
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/153838 |
Sep 1999 |
US |